130 related articles for article (PubMed ID: 23090679)
1. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia.
Janes MR; Vu C; Mallya S; Shieh MP; Limon JJ; Li LS; Jessen KA; Martin MB; Ren P; Lilly MB; Sender LS; Liu Y; Rommel C; Fruman DA
Leukemia; 2013 Mar; 27(3):586-94. PubMed ID: 23090679
[TBL] [Abstract][Full Text] [Related]
2. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.
Maude SL; Tasian SK; Vincent T; Hall JW; Sheen C; Roberts KG; Seif AE; Barrett DM; Chen IM; Collins JR; Mullighan CG; Hunger SP; Harvey RC; Willman CL; Fridman JS; Loh ML; Grupp SA; Teachey DT
Blood; 2012 Oct; 120(17):3510-8. PubMed ID: 22955920
[TBL] [Abstract][Full Text] [Related]
3. Mtor inhibition by INK128 extends functions of the ovary reconstituted from germline stem cells in aging and premature aging mice.
Heng D; Sheng X; Tian C; Li J; Liu L; Gou M; Liu L
Aging Cell; 2021 Feb; 20(2):e13304. PubMed ID: 33448083
[TBL] [Abstract][Full Text] [Related]
4. Directly imaging the localisation and photosensitization properties of the pan-mTOR inhibitor, AZD2014, in living cancer cells.
Ahmed AR; Candeo A; D'Abrantes S; Needham SR; Yadav RB; Botchway SW; Parker AW
J Photochem Photobiol B; 2020 Dec; 213():112055. PubMed ID: 33142217
[TBL] [Abstract][Full Text] [Related]
5. Targeting mTOR for the treatment of B cell malignancies.
Lee JS; Vo TT; Fruman DA
Br J Clin Pharmacol; 2016 Nov; 82(5):1213-1228. PubMed ID: 26805380
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia.
Al-Kali A; Aldoss I; Atherton PJ; Strand CA; Shah B; Webster J; Bhatnagar B; Flatten KS; Peterson KL; Schneider PA; Buhrow SA; Kong J; Reid JM; Adjei AA; Kaufmann SH
Cancer Med; 2023 Dec; 12(23):21229-21239. PubMed ID: 37960985
[TBL] [Abstract][Full Text] [Related]
7. Kinase-independent role of mTOR and on-/off-target effects of an mTOR kinase inhibitor.
Fan C; Wunderlich M; Cai X; Yan Z; Zhang F; Davis AK; Xu L; Guo F; Lu QR; Azam M; Tian W; Zheng Y
Leukemia; 2023 Oct; 37(10):2073-2081. PubMed ID: 37532788
[TBL] [Abstract][Full Text] [Related]
8. MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.
Slotkin EK; Patwardhan PP; Vasudeva SD; de Stanchina E; Tap WD; Schwartz GK
Mol Cancer Ther; 2015 Feb; 14(2):395-406. PubMed ID: 25519700
[TBL] [Abstract][Full Text] [Related]
9. mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling.
Zhang H; Dou J; Yu Y; Zhao Y; Fan Y; Cheng J; Xu X; Liu W; Guan S; Chen Z; shi Y; Patel R; Vasudevan SA; Zage PE; Zhang H; Nuchtern JG; Kim ES; Fu S; Yang J
Apoptosis; 2015 Jan; 20(1):50-62. PubMed ID: 25425103
[TBL] [Abstract][Full Text] [Related]
10. The ATP-competitive mTOR inhibitor INK128 enhances in vitro and in vivo radiosensitivity of pancreatic carcinoma cells.
Hayman TJ; Wahba A; Rath BH; Bae H; Kramp T; Shankavaram UT; Camphausen K; Tofilon PJ
Clin Cancer Res; 2014 Jan; 20(1):110-9. PubMed ID: 24198241
[TBL] [Abstract][Full Text] [Related]
11. The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent.
Li C; Cui JF; Chen MB; Liu CY; Liu F; Zhang QD; Zou J; Lu PH
Cancer Biol Ther; 2015; 16(1):34-42. PubMed ID: 25692620
[TBL] [Abstract][Full Text] [Related]
12. Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis.
Guo Y; Kwiatkowski DJ
Mol Cancer Res; 2013 May; 11(5):467-73. PubMed ID: 23386687
[TBL] [Abstract][Full Text] [Related]
13. Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program.
Kang MH; Reynolds CP; Maris JM; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Wu J; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2014 Aug; 61(8):1486-9. PubMed ID: 24623675
[TBL] [Abstract][Full Text] [Related]
14. TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.
Burris HA; Kurkjian CD; Hart L; Pant S; Murphy PB; Jones SF; Neuwirth R; Patel CG; Zohren F; Infante JR
Cancer Chemother Pharmacol; 2017 Aug; 80(2):261-273. PubMed ID: 28601972
[TBL] [Abstract][Full Text] [Related]
15. MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells.
Zeng Z; Wang RY; Qiu YH; Mak DH; Coombes K; Yoo SY; Zhang Q; Jessen K; Liu Y; Rommel C; Fruman DA; Kantarjian HM; Kornblau SM; Andreeff M; Konopleva M
Oncotarget; 2016 Aug; 7(34):55083-55097. PubMed ID: 27391151
[TBL] [Abstract][Full Text] [Related]
16. mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells.
Beagle BR; Nguyen DM; Mallya S; Tang SS; Lu M; Zeng Z; Konopleva M; Vo TT; Fruman DA
Oncotarget; 2015 Feb; 6(4):2088-100. PubMed ID: 25576920
[TBL] [Abstract][Full Text] [Related]
17. Pleiotropic roles of mTOR complexes in haemato-lymphopoiesis and leukemogenesis.
Hoshii T; Matsuda S; Hirao A
J Biochem; 2014 Aug; 156(2):73-83. PubMed ID: 24962700
[TBL] [Abstract][Full Text] [Related]
18. Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies.
Eyre TA; Collins GP; Goldstone AH; Cwynarski K
Br J Haematol; 2014 Aug; 166(3):336-51. PubMed ID: 24842496
[TBL] [Abstract][Full Text] [Related]
19. DNA-scaffolded multivalent ligands to modulate cell function.
Zhang Z; Eckert MA; Ali MM; Liu L; Kang DK; Chang E; Pone EJ; Sender LS; Fruman DA; Zhao W
Chembiochem; 2014 Jun; 15(9):1268-73. PubMed ID: 24803415
[TBL] [Abstract][Full Text] [Related]
20. Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1.
Mallya S; Fitch BA; Lee JS; So L; Janes MR; Fruman DA
PLoS One; 2014; 9(2):e88865. PubMed ID: 24586420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
